Alpha-9 Oncology (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- October 23, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $175,000,000
Company Info
- Founders
- David Hirsch
- Company Description
- Alpha-9 Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects.
- Market
- Oncology
- Location
- Boston, MA, USA
- Coinvestors
- A16z, abrdn, Ascenta Capital, BVF Partners, Delos Capital, Digitalis Ventures, Frazier Life Sciences, General Catalyst Partners, Janus Henderson Investors, Lightspeed Venture Partners, Longitude Capital, Lumira Ventures, Nextech Invest, RA Capital Management, Samsara BioCapital